Tags & Categorías

PBM Says Its Biosimilars Strategy Led to 86% Use of Biosimilar Infliximab

Magellan Rx Management, a pharmacy benefit manager (PBM), said today that its biosimilar management program has resulted in strong biosimilar uptake a...

Laboratorios Stada lanzará en 2019 su primer biosimilar en España

La compañía prevé sacar al mercado el biosimilar de teriparatida a finales de 2019, así como un conjunto de medicamentos de especialización en la...

Study Reports Long-Term Similarity Between ABP 501 and Humira in Patients With RA

The study is an open-label extension of a phase 3 trial that included 68 weeks of treatment with the biosimilar adalimumab, Amjevita, followed by an a...

El biosimilar de trastuzumab ya está disponible para cáncer de mama y gástrico

Se trata de Trazimera y está indicado para los casos de cáncer de mama HER2+, en fases iniciales como metastásicas, y cáncer gástrico HER2+ metas...

Comparison of autoinjectors for inflammatory joint or bowel disease

Imraldi is a biosimilar of the antitumour necrosis factor (TNF) monoclonal antibody adalimumab. It was approved in Europe in August 2017 for the treat...

Head-to-Head Study Shows CT-P13 Is Noninferior to Reference Infliximab in CD

Approval of biosimilars in indications for which they were not studied directly in phase 3 clinical trials relies of the extrapolation of indications,...

How can EU policymakers access the potential of biosimilars

Policymakers in Europe should introduce a long-term, multi-stakeholder framework to realize the full potential of off-patent biologicals and biosimila...

Biosimilars Benefit Patients With Expanded Access, but Physicians Still Need Education

Patient access to treatment has improved in many countries since the advent of biosimilars, where access to biologic treatments is variable among nati...

Samsumg Bioepis muestra que la comparabilidad de su biosimilar de trastuzumab se mantiene en el tiem...

Samsung Bioepis ha presentado, en el marco del 16º Congreso Internacional de Cáncer de Mama St. Gallen 2019, celebrado en Viena (Austria), los resul...

Samsung Bioepis announced three-year follow-up data for biosimilar Ontruzant (trastuzumab) in early ...

Samsung Bioepis Co., Ltd. announced findings of a three-year follow-up study comparing biosimilar Ontruzant (trastuzumab) and reference medicine trast...